We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
COLO-B.CO

Price
786.20
Stock movement down
-8.60 (-1.08%)
Company name
Coloplast A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Medical Instruments & Supplies
Markedsværdi
163.01B
Ent værdi
192.35B
Pris/omsætning
6.03
Pris/bog
9.09
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
320.65%
Efterfølgende P/E
32.27
Fremtidig P/E
28.84
PEG
-
EPS-vekst
4.33%
1 års afkast
1.08%
3 års afkast
-11.79%
5 års afkast
-0.27%
10 års afkast
4.25%
Senest opdateret: 2025-01-02

UDBYTTE

COLO-B.CO betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E32.27
Pris til OCF58.93
Pris til FCF110.74
Pris til EBITDA37.44
EV i forhold til EBITDA44.18

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning6.03
Pris til egenkapital9.09
EV i forhold til salg7.12

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier207.34M
EPS (TTM)22.45
FCF pr. aktie (TTM)6.54

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)27.03B
Bruttofortjeneste (TTM)18.27B
Driftsindkomst (TTM)7.37B
Nettoindkomst (TTM)5.05B
EPS (TTM)22.45
EPS (1 år frem)27.26

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)67.59%
Driftsmargin (TTM)27.25%
Fortjenstmargin (TTM)18.69%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter788.00M
Nettotilgodehavender4.67B
Omsætningsaktiver i alt10.44B
Goodwill19.38B
Immaterielle aktiver10.96B
Ejendomme, anlæg og udstyr13.27B
Sum aktiver48.07B
Kreditor1.52B
Kortfristet/nuværende langsigtet gæld22.63B
Summen af kortfristede forpligtelser10.20B
Sum gæld30.13B
Aktionærernes egenkapital17.94B
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)2.77B
Investeringsudgifter (TTM)1.29B
Fri pengestrøm (TTM)1.47B
Udbetalt udbytte (TTM)4.72B

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast28.16%
Afkast af aktiver10.51%
Afkast af investeret kapital12.60%
Kontant afkast af investeret kapital3.67%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning793.60
Daglig høj794.60
Daglig lav784.80
Daglig volumen103K
Højeste gennem alle tider1182.50
1 års analytiker estimat926.10
Beta0.34
EPS (TTM)22.45
Udbytte pr. aktie-
Ex-div dato6 Dec 2024
Næste dato for resultatpræsentation4 Feb 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
COLO-B.COS&P500
Nuværende prisfald fra top notering-33.51%-3.22%
Højeste prisfald-43.67%-56.47%
Højeste efterår dato28 Oct 19949 Mar 2009
Gennemsnitlig fald fra toppen-11.74%-11.12%
Gennemsnitlig tid til nyt højdepunkt16 days12 days
Maks. tid til nyt højdepunkt857 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
COLO-B.CO (Coloplast A/S) company logo
Markedsværdi
163.01B
Markedsværdi kategori
Large-cap
Beskrivelse
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Personale
16639
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Denmark
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved.Distribution of ye...
5. december 2024
The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted t...
4. december 2024
On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based produc...
14. november 2024
The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk...
12. november 2024
Coloplast AS (CLPBF) reports robust financial performance with 8% organic growth and strategic product launches, despite facing supply disruptions and competitive pressures.
6. november 2024
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million. Organic growth rates b...
5. november 2024
2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraord...
5. november 2024
Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect. “We have entered the final year of...
5. november 2024
Earnings preview of key companies reporting this week and what to look out for.
1. november 2024
Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial...
21. oktober 2024
Næste side